Drug Trial Radar · NCT06534437
MEN1703 (SEL24) to Treat Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma (JASPIS-01)
Last checked: Nov 19, 2026Latest source record: Sep 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
178
Planned (sponsor's estimate)
Start
Dec 5, 2024
Primary completion
Dec 2026
Study completion Dec 2026
Sponsor
- Lead sponsor
- Ryvu Therapeutics SAIndustry
- Sponsor type
- Industry
- Collaborators
- Menarini Group
- First posted
- Aug 2, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of the study is to assess the safety and anti-lymphoma activity of MEN1703 (Dapolsertib hydrochloride) when given as a single-agent or combined with glofitamab to patients with relapsed/refractory (R/R) aggressive B-cell non-Hodgkin lymphoma. The study will be open to groups at the same time: * Group 1 - patients who have not had anti-CD3xCD20 bispecific antibody therapy but who have had at least 2 prior lines of systemic treatment for aggressive B-cell non-Hodgkin lymphoma * Group 2 - patients who have exhausted all standard treatment options including at least 2 prior lines of systemic treatment for aggressive B-cell non-Hodgkin lymphoma Group 1 patients will be treated for a maximum of 12 cycles. One cycle is 21 days. Group 2 with be treated until the disease progresses, therefore treatment duration is dependent on the number of treatment cycles a participant receives prior to progression.
Conditions
- Non-Hodgkin Lymphoma, B-cell
Interventions
MEN1703Drug
MEN1703 (Dapolsertib hydrochloride) is a potent dual inhibitor of proviral integration site for Moloney murine leukemia virus (PIM) kinases and Fms-like tyrosine kinase 3 (FLT3).
GlofitamabDrug
Glofitamab is a bispecific monoclonal antibody that binds bivalently to CD20 expressed on the surface of B-cells and monovalently to CD3 in the T-cell receptor complex expressed on the surface of T-cells.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part 1: Incidence and severity of adverse events (AE)Time frame: 12 months
- Part 2 and Part 3: Complete response (CR) (group 1)Time frame: 12 months
- Part 2 and Part 3: Overall response rate (group 2)Time frame: 12 months
Locations
35 sites in 4 countries. Site status is shown where the registry gives one.
Centre Hospitalier Le Mans
Le Mans, France · Recruiting
CHU de Lille - Hôpital Claude Huriez
Lille, France · Recruiting
CHU de Limoges - CHU Dupuytren
Limoges, France · Recruiting
Hospices Civils De Lyon - Hôpital Lyon Sud
Lyon, France · Recruiting
CHU Montpellier - Hôpital Saint Eloi
Montpellier, France · Recruiting
APHP - Hôpital Pitié-Salpêtrière
Paris, France · Recruiting
CHU de Bordeaux - Hôpital Haut-Lévêque
Pessac, France · Recruiting
Wojewódzki Szpital Specjalistyczny w Białej Podlaskiej
Biała Podlaska, Poland · Terminated
IN-VIVO Bydgoszcz Sp. z o.o.
Bydgoszcz, Poland · Recruiting
Klinika Hematologii I Transplantologii Uck
Gdansk, Poland · Not yet recruiting
Szpitale Pomorskie Sp. z o.o.
Gdynia, Poland · Recruiting
Narodowy Instytut Onkologii im. Marii Skłodowskiej Curie, Państwowy Instytut Badawczy
Gliwice, Poland · Recruiting
Pratia Hematologia Sp. z o.o.
Katowice, Poland · Terminated
Pratia MCM Kraków
Krakow, Poland · Recruiting
SP ZOZ Szpital Uniwersytecki w Krakowie
Krakow, Poland · Recruiting
Szpital Kliniczny Ministerstwa Spraw Wewnętrznych i Administracji z Warmińsko-Mazurskim Centrum Onkologii w Olsztynie
Olsztyn, Poland · Recruiting
Aidport Sp. z o.o.
Skórzewo, Poland · Recruiting
Wojewódzki Szpital Zespolony im. L. Rydygiera w Toruniu
Torun, Poland · Recruiting
Lux Med Onkologia Sp. z o.o.
Warsaw, Poland · Terminated
Wojskowy Instytut Medyczny - Państwowy Instytut Badawczy
Warsaw, Poland · Terminated
Hospital Universitari Vall D Hebron
Barcelona, Spain · Recruiting
Clinica Universidad De Navarra
Madrid, Spain · Recruiting
MD Anderson Cancer Center
Madrid, Spain · Recruiting
Hospital Universitario Puerta de Hierro Majadahonda
Madrid, Spain · Recruiting
Hospital Clínico Uni versitario Virgen de la Arrixaca
Murcia, Spain · Not yet recruiting
Clinica Universidad De Navarra
Pamplona, Spain · Recruiting
Hospital Universitario De Navarra
Pamplona, Spain · Recruiting
Hospital Universitario De Salamanca
Salamanca, Spain · Recruiting
Hospital Universitario Virgen De La Macarena
Seville, Spain · Recruiting
Hospital Universitario Miguel Servet
Zaragoza, Spain · Recruiting
Beatson West of Scotland Cancer Centre
Glasgow, United Kingdom · Recruiting
The Christie NHS Foundation Trust
Manchester, United Kingdom · Recruiting
Plymouth Hospitals NHS Trust
Plymouth, United Kingdom · Recruiting
The Royal Marsden Hospital
Sutton, United Kingdom · Recruiting
St George's Hospital
Tooting, United Kingdom · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.